| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 134.22 | 10.0% | 12.0% |
| Total Income | 134.22 | 10.0% | 12.0% |
| Expenditure | 83.21 | 5.1% | 3.8% |
| PBT | 47.52 | 18.5% | 29.3% |
| Net Profit | 36.43 | 6.5% | 1.4% |
| OPM | 38.01% | 2.92pp | 4.93pp |
| NPM | 27.14% | 0.91pp | 2.82pp |
| EPS | 0.15 | 7.1% | 0.0% |
ADMA Biologics Reports Q3 2025 Revenue of $134.2M, Up 12% YoY
04 May 2026 · 4 May, 7:59 am
Summary
ADMA Biologics announced its third quarter 2025 financial results, reporting a 12% increase in total revenue to $134.2 million. GAAP net income increased by 1% to $36.4 million, while adjusted EBITDA rose by 29% to $58.7 million. The company is raising its full-year 2025 revenue guidance to at least $510 million and its full-year 2026 revenue guidance to at least $630 million. Management anticipates total annual revenue to exceed $1.1 billion in FY 2029.
Key Highlights
- 1
Third quarter 2025 total revenue reached $134.2 million, reflecting a 12% increase year-over-year.
- 2
GAAP net income for the third quarter 2025 was $36.4 million, a 1% increase year-over-year.
- 3
Adjusted EBITDA for the third quarter 2025 was $58.7 million, representing a 29% increase year-over-year.
- 4
Adjusted net income for the third quarter 2025 was $38.9 million, an 8% increase year-over-year.
- 5
The FDA lot release of first yield-enhanced production batches positions ADMA for margin expansion beginning in Q4 2025 and continuing through 2026.
- 6
The company is raising FY 2025 total revenue guidance to $510 million or more and FY 2026 total revenue guidance to $630 million or more.
- 7
FY 2029 total annual revenue is projected to exceed $1.1 billion with anticipated outsized earnings growth.
Management Comments
Adam Grossman
ADMA is executing from a position of strength as we enter our next phase of disciplined, profitable growth. The FDA lot release of our first yield‑enhanced production batches marks a pivotal milestone expected to drive sustained gross margin expansion beginning in the fourth quarter of 2025 and through 2026 and beyond. Record ASCENIV utilization and ongoing constructive negotiations with payers for enhanced 2026 reimbursement and access underscore the durable and growing demand for our differentiated plasma‑derived biologics portfolio. In parallel, we continue to work towards operational efficiency and a disciplined capital deployment strategy. Supported by a strong balance sheet, robust forecasted cash generation, continued advancement of our SG‑001 pipeline program and organically funded share repurchases, we believe ADMA is well‑positioned to deliver accelerating earnings growth, expanding margins, and stockholder value creation.
Informational and educational content only. Not investment advice.